Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06986434) titled 'CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms' on May 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
Condition:
Relapsed or Refractory Plasma Cell Neoplasms
Intervention:
Genetic: CAR19BCMA-T cells
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: May 22, 2025
Target Sample Size: 20
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.go...